A Multicentre, Open-Label, Repeated Measures, Phase 2a Clinical Pilot Trial Background Since the 1990’s attempts to favorably modulate nitric oxide (NO) have been unsuccessful. We hypothesized that because NO is…
A novel strategy to mitigate massive nitric oxide release and prevent reperfusion injury in septic shock Background Nitric oxide plays a critical role in regulating vascular tone, but excessive nitric…
Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, announced its participation in BIO Partnering @ JPM Week 2025 in San Francisco January 13-16. During the…
KANSAS CITY, Mo., Sept. 24, 2024 /PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced its support of the Sepsis Alliance in…
Vivacelle Bio on the Empowered Patient Podcast with Karen Jagoda Dr. Harven DeShield is the CEO and Co-Founder of Vivacelle Bio, which is developing a nanoparticle-based treatment called VBI-S to address…
KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced that it has enrolled the first patient…
Vivacelle's VBI-S is designed to treat hypovolemic patients in urgent need of care due to septic shock Septic shock impacts approximately two million people in the U.S. each year, the…
Vivacelle is advancing a robust pipeline of therapies for shock and trauma-induced conditions Vivacelle's pipeline is led by VBI-S, a Phase 3-ready asset designated for the treatment of hypotension and…
KANSAS CITY, Mo., Feb. 29, 2024 /PRNewswire/ -- Today, researchers at Vivacelle Bio, Inc., a pioneering biotechnology company revealed the compelling outcomes of their phase 2a clinical trial of the…
